Navigation Links
Data from In Vivo Disease Models on Taligen Therapeutics' Pipeline Candidates to be Presented at the XXII International Complement Workshop
Date:9/25/2008

Presentations Include Proof-of-Concept Animal Data on Previously Disclosed Fusion Protein TT30 and New Molecules TT32 and mAb171

CAMBRIDGE, Mass., Sept. 25 /PRNewswire/ -- Taligen Therapeutics Inc. today announced that data from in vivo disease models on several of the company's pipeline candidates will be presented next week at the XXII International Complement Workshop in Basel, Switzerland.

The data, which will be presented in eight oral and poster presentations, are the results of research conducted by the laboratories of Michael Holers, M.D., chief scientific officer of Taligen, and the company's academic collaborators in the complement research community. Five studies testing the company's fusion protein TT30 and two new compounds, a fusion protein TT32 and a monoclonal antibody mAb171, in animal models are highlighted below. These data further support Taligen's approach that targeting the alternative complement pathway can impact complement-mediated inflammatory disease processes.

Poster Presentations:

TT30

Targeted inhibition of the alternative pathway by CR2-fH fusion protein ameliorates progression of renal disease in MRL/lpr mice

Hideharu Sekine*, Gary Gilkeson, Stephen Tomlinson

Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 174

Alternative complement pathway signaling in a mouse model of choroidal neovascularisation

Barbel Rohrer*, Qin Long, Brooks Wilson, Beth Coughlin, Yuxiang Huang, Fei Qiao, Peter Tang, Kannan Kunchithapautham, Gary Gilkeson, Stephen Tomlinson

Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 202

TT30 and TT32

Targeted complement-inhibitory proteins CR2-Crry and CR2-fH ameliorate allergen-induced airway hyperresponsiveness and inflammation

Joshua Thurman*, Katsuyuki Takeda, Stephen Tomlinson, Erwin Gelfand, V. Michael Holers

Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 171

The role
'/>"/>

SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
2. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
3. Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
4. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
5. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
6. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
7. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
8. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
9. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
10. Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
11. SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... (NYSE: EW ), the global leader in the ... net income for the quarter ended June 30, 2015 of ... income on a non-GAAP basis was $124.4 million, or ... share in the prior year period. In the year ... share, which included a $750 million payment to Edwards ...
(Date:7/28/2015)... 28, 2015   Regulus Therapeutics Inc . ( ... and development of innovative medicines targeting microRNAs, today announced ... the quarter ended June 30, 2015 on Tuesday, August ... Regulus will host a conference call and ... Eastern Daylight Time to discuss its second quarter 2015 ...
(Date:7/28/2015)... LOUIS, July 28, 2015  Express Scripts Holding Company ... income attributable to Express Scripts stockholders of $600.1 million, ... share, as detailed in Table 4, were $1.44 for ... is clear many companies across healthcare are validating the ... and Chief Executive Officer. "But, what matters most is ...
Breaking Medicine Technology:Edwards Lifesciences Reports Second Quarter Results 2Edwards Lifesciences Reports Second Quarter Results 3Edwards Lifesciences Reports Second Quarter Results 4Edwards Lifesciences Reports Second Quarter Results 5Edwards Lifesciences Reports Second Quarter Results 6Edwards Lifesciences Reports Second Quarter Results 7Edwards Lifesciences Reports Second Quarter Results 8Edwards Lifesciences Reports Second Quarter Results 9Edwards Lifesciences Reports Second Quarter Results 10Edwards Lifesciences Reports Second Quarter Results 11Edwards Lifesciences Reports Second Quarter Results 12Edwards Lifesciences Reports Second Quarter Results 13Edwards Lifesciences Reports Second Quarter Results 14Edwards Lifesciences Reports Second Quarter Results 15Edwards Lifesciences Reports Second Quarter Results 16Edwards Lifesciences Reports Second Quarter Results 17Edwards Lifesciences Reports Second Quarter Results 18Edwards Lifesciences Reports Second Quarter Results 19Edwards Lifesciences Reports Second Quarter Results 20Edwards Lifesciences Reports Second Quarter Results 21Edwards Lifesciences Reports Second Quarter Results 22Edwards Lifesciences Reports Second Quarter Results 23Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 2Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 4Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 5Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 6Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 7Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 8Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 9Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 10Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 11Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 12
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... gateways, and embedded building blocks for edge devices that enable the Internet of ... 4th generation Intel® Core™ i7/i5 processor to provide exceptional computing power and multitasking ...
(Date:7/28/2015)... ... July 28, 2015 , ... opaJUMP! ... measure and produce health outcomes associated with its training methods. This company is ... small group pre-post study, conducted in early 2015, training yielded an average 80% ...
(Date:7/28/2015)... ... ... Master flutist and solo artist Gary Stroutsos shares his deep resume of ... of serene, restorative instrumental music. Tracks carefully curated by White Swan producer Dubgoddess ... more -- to help the listener deeply breathe in a healing inner light for ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Egg freezing ... the procedure to help ensure future fertility. As Dr. Michael Kettel explained ... freezing is an option that wasn’t available for previous generations who had to make ...
(Date:7/28/2015)... ... ... to Kxan on June 24th a previously FDA approved blood pressure medication ... isradipine has garnered national attention and is making drug and alcohol rehabilitation medical physicians ... The study was conducted by the University of Texas. Human trials may be set ...
Breaking Medicine News(10 mins):Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 2Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 3Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 2Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 3Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 4Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 5Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 6Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 7Health News:Flute Meditations for Yoga & Massage: Calming Spa Music for Relaxation & Sleep by Gary Stroutsos 2Health News:Flute Meditations for Yoga & Massage: Calming Spa Music for Relaxation & Sleep by Gary Stroutsos 3Health News:Flute Meditations for Yoga & Massage: Calming Spa Music for Relaxation & Sleep by Gary Stroutsos 4Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 2Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 3Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3
... Pain and Heat cannot coexist, because heat is capable of ... the use of DNA technology//, scientists were able to understand ... the heat is on, it has a pain relieving effect. ... par with a pain killer, because pain receptors are turned ...
... undergoing multiple tests to diagnose and investigate cardiovascular ... seemed to be promoted //by advanced imaging modalities. ... has recommended that an inter-disciplinary collaboration of various ... diagnosis could ensure effective diagnosis of heart diseases ...
... Medical Research (MIMR) have developed a new machine, named ... constantly. ,Although it was the first ... continuously, the fluctuating BP and brain oxygen levels of ... Monash Institute of Medical Research (MIMR) are carrying out ...
... University of Bristol have recommended that knee cartilage injuries ... any signs of osteoarthritis progression. ,'The ... only about 12 months and this is the first ... ,The study, 'Maturation of tissue engineered cartilage implanted ...
... whose parents were diagnosed with HIV was driven to ... ,Santosh Baniya succumbed to his burn injuries ... week. ,The boy’s parents, both vegetable sellers, ... have suggested that Santosh Baniya feared surviving his parents ...
... to a research conducted by Stephanie Chiuve it was found ... ailments//. ,U.S. researchers stated that patients suffering from ... lifestyle. ,It was discussed that middle aged men ... a proper diet and change their drinking and smoking habits. ...
Cached Medicine News:Health News:Collaborative use of Imaging Techniques proved effective in Cardiovascular Diagnosis – ESC Recommend 2Health News:Collaborative use of Imaging Techniques proved effective in Cardiovascular Diagnosis – ESC Recommend 3Health News:Preterm Babies Benefited from a New NI Spectroscopy 2Health News:Engineered Tissue Implants benefited Knee Injured patients 2
Gamma Glutamyl Transferase reagent is used for the quantitative determination of Gamma -GT in human serum....
For the quantitative kinetic determination of amylase activity, using manual or automated procedures, in human serum and urine....
For quantitative determination of amylase in human serum....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Medicine Products: